인쇄하기
취소

Yuhan Corporation & Samsung Bioepis sign exclusive biosimilar sales agreement

Published: 2017-10-13 15:36:46
Updated: 2017-10-13 15:36:46

Yuhan Corporation(CEO Jung-Hee Lee) signed an exclusive sales agreement of the Remicade(generic name: infliximab) biosimilar(SB2) and the Enbrel(generic name: etanercept) biosimilar(SB4) in Korea with Samsung Bioepis(CEO Han-Seung Ko).

The Remicade biosimilar(SB2) and the Enbrel biosimilar(SB4) are antibodies developed by Samsung Bioepis through foreign and Korean clinical trials, and are TNF-...

Fees

- Email service daily and homepage access.
  1. $300 per month.
  2. 5 Email holders per each company.
  3. Anual contract base.
Copyright Yakup.com All rights reserved.
약업닷컴의 모든 컨텐츠는 저작권법의 보호를 받습니다. 무단 전재⋅복사⋅배포 등을 금합니다.